Employees: 601
Size Strata Critical Medical (SRTA) is a United States Health Care company (Medical/Nursing Services) with a market value of $443M, the 2760th largest of 3,085 United States companies the cockpit tracks. Shares closed at $4.96 on 18 Nov 2026.
Performance Over six months the shares fell 10.5%, against -3.5% for the median peer and -2.2% for the United States market (cap-weighted) — 6th lowest of 20 in its peer set.
Growth Revenue grew 22.7% over the last twelve months (peer median +5.1%); the operating margin is -4.2% (peer median 8.4%).
Valuation It trades at 86.3× forward earnings against a peer median of 16.9× (most expensive of 13).
Capital Return on invested capital runs 21.7 points below its cost of capital (17.8% WACC).
Next results Next results expected around 16 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $281M | $197M | $147M | $225M | $146M |
| Revenue growth | — | +34% | -35% | +54% | — |
| Gross profit | $42.7M | $38.3M | $28.0M | $36.1M | $17.4M |
| EBITDA | $10.2M | -$2.91M | -$15.3M | -$61.0M | -$44.8M |
| Net income | -$21.0M | -$15.6M | -$27.3M | -$56.1M | -$27.3M |
| Free cash flow | -$737,000 | -$59.9M | -$35.5M | -$34.5M | -$37.9M |
| Capital expenditure | $11.1M | $11.0M | $33.0M | $2.11M | $730,000 |
| Total debt | $3.62M | $3.31M | $3.02M | $24.5M | $18.3M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | SRTA | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +5.8% | -9.6% | 6th highest of 21 |
| 6-month return | -10.5% | -3.5% | 6th lowest of 20 |
| Distance from 52-week high | -23.7% | -30.8% | 8th highest of 21 |
| Revenue growth (TTM) | +22.7% | +5.1% | 7th highest of 21 |
| Operating margin | -4.2% | 8.4% | 4th lowest of 21 |
| Forward P/E | 86.3× | 16.9× | most expensive of 13 |
| ROIC minus cost of capital | -21.7 pp | -0.3 pp | 4th lowest of 20 |
| Net debt / EBITDA | -3.8× | 1.6× | least indebted of 14 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Strata Critical Medical SRTA | United States | $443M | -10% | +23% | -4% | 86.3× | n/a | n/a |
| JS Link 127120.KS | South Korea | $458M | -62% | +39% | -83% | n/a | n/a | n/a |
| Australian Clinical Labs ACL.AX | Australia | $418M | +68% | -1% | 8% | 17.8× | 4.3% | +2.6% |
| Integral Diagnostics IDX.AX | Australia | $413M | -22% | +26% | 9% | 14.7× | 7.8% | +17.7% |
| Jeena Sikho Lifecare JSLL.NS | India | $394M | -55% | +135% | 32% | 17.4× | 7.3% | +42.6% |
| ADICON 9860.HK | Hong Kong | $393M | +5% | +1% | 4% | 24.6× | 12.3% | -1.5% |
| Shanghai Labway Clinical Laboratory 301060.SZ | China | $518M | -17% | -19% | 6% | n/a | 5.9% | +3.2% |
| M1 Kliniken M12.DE | Germany | $368M | +1% | -28% | 13% | 16.4× | -5.3% | +17.9% |
| Ginkgo Bioworks DNA | United States | $547M | +9% | -44% | -242% | n/a | n/a | n/a |
| Australian Unity Ltd Pref AYUPA.AX | Australia | $352M | +17% | 0% | -2% | n/a | -14.9% | +9.6% |
| Tellgen 300642.SZ | China | $328M | -11% | +5% | 8% | n/a | 18.8% | -5.8% |
| Oncology Institute STLN | United States | $326M | n/a | +35% | -3% | n/a | 5.4% | +21.8% |
| NIOX NIOX.L | United Kingdom | $325M | +3% | +3% | 22% | 19.8× | 3.4% | +15.3% |
| Auna AUNA | United States | $309M | -5% | +17% | 13% | 4.1× | -10.7% | +24.4% |
| Universal Vision Biotechnology 3218.TWO | Taiwan | $309M | -4% | +5% | 31% | 9.2× | -13.8% | +15.4% |
| WELL Health Technologies WELL.TO | Canada | $661M | -9% | +29% | 6% | 10.1× | 10.1% | +94.5% |
| Dr. Agarwal'S Eye Hospital DRAGARWQ.NS | India | $292M | +14% | +20% | 21% | n/a | 19.6% | +27.5% |
| Fulgent Genetics FLGT | United States | $702M | +53% | +5% | -38% | n/a | n/a | n/a |
| Nephrocare Health Services NEPHROPLUS.NS | India | $702M | +1% | +33% | 13% | 48.8× | 36.6% | +31.6% |
| GMR Solutions GMRS | United States | $714M | -8% | -4% | 14% | 5.9× | -19.6% | -4.0% |
| Jinxin Fertility 1951.HK | Hong Kong | $758M | -4% | +7% | 11% | 23.1× | 17.8% | +12.4% |